Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
Ceramide Kinase / CERK Antibody (Internal)
Rabbit Polyclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| IHC-P |
|---|---|
| Primary Accession | Q8TCT0 |
| Reactivity | Human, Monkey |
| Host | Rabbit |
| Clonality | Polyclonal |
| Calculated MW | 60kDa |
| Dilution | IHC-P (20 µg/ml) |
| Gene ID | 64781 |
|---|---|
| Other Names | Ceramide kinase, hCERK, 2.7.1.138, Acylsphingosine kinase, Lipid kinase 4, LK4, CERK, KIAA1646 |
| Target/Specificity | Human CERK. BLAST analysis of the peptide immunogen showed no homology with other human proteins. |
| Reconstitution & Storage | Long term: -70°C; Short term: +4°C |
| Precautions | Ceramide Kinase / CERK Antibody (Internal) is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | CERK |
|---|---|
| Synonyms | KIAA1646 |
| Function | Catalyzes specifically the phosphorylation of ceramide to form ceramide 1-phosphate (PubMed:11956206, PubMed:16269826, PubMed:19168031). Acts efficiently on natural and analog ceramides (C6, C8, C16 ceramides, and C8-dihydroceramide), to a lesser extent on C2- ceramide and C6-dihydroceramide, but not on other lipids, such as various sphingosines (PubMed:11956206, PubMed:16269826, PubMed:19168031). Shows a greater preference for D-erythro isomer of ceramides (PubMed:16269826). Binds phosphoinositides (PubMed:19168031). |
| Cellular Location | Cytoplasm. Cell membrane; Peripheral membrane protein |
| Tissue Location | High level expression in heart, brain, skeletal muscle, kidney and liver; moderate in peripheral blood leukocytes and thymus; very low in spleen, small intestine, placenta and lung |
| Volume | 50 µl |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Catalyzes specifically the phosphorylation of ceramide to form ceramide 1-phosphate. Acts efficiently on natural and analog ceramides (C6, C8, C16 ceramides, and C8-dihydroceramide), to a lesser extent on C2-ceramide and C6-dihydroceramide, but not on other lipids, such as various sphingosines. Binds phosphoinositides.
References
Sugiura M.,et al.J. Biol. Chem. 277:23294-23300(2002).
Van Veldhoven P.P.,et al.Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
Collins J.E.,et al.Genome Biol. 5:R84.1-R84.11(2004).
Ota T.,et al.Nat. Genet. 36:40-45(2004).
Dunham I.,et al.Nature 402:489-495(1999).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
